QuidelOrtho Corp (NASDAQ:QDEL)
| Market Cap | 818.97M-56.9% |
| Revenue (ttm) | 2.67B-2.5% |
| Net Income | -1.05B-124.8% |
| EPS | -15.44-136.1% |
| Shares Out | 68.19M |
| PE Ratio | n/a |
| Forward PE | 8.33 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 240,895.131 |
| Open | 12.09 |
| Previous Close | 12.31 |
| Day's Range | 11.72 - 12.09 |
| 52-Week Range | 9.92 - 35.58 |
| Beta | 0.68 |
| Analysts | Hold |
| Price Target | 12.25(+2.00%) |
| Earnings Date | Nov 4, 2026 |
Insiders here have filed 4 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About QDEL
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
$QDEL stock is featured in our Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of QDEL by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Gilbert Ray CisnerosHouse / D | Sale$1.00K – $15.00K | Nov 13, 2020 |
| Gilbert CisnerosHouse / D | Sale$1.00K – $15.00K | Nov 13, 2020 |
| Gilbert Ray CisnerosHouse / D | Sale$1.00K – $15.00K | Nov 12, 2020 |
| Gilbert CisnerosHouse / D | Sale$1.00K – $15.00K | Jul 30, 2020 |
| Gilbert Ray CisnerosHouse / D | Sale$1.00K – $15.00K | Jul 30, 2020 |
| Gilbert Ray CisnerosHouse / D | Sale$1.00K – $15.00K | Jul 29, 2020 |
| Gilbert CisnerosHouse / D | Sale$1.00K – $15.00K | Jul 13, 2020 |
| Gilbert Ray CisnerosHouse / D | Sale$1.00K – $15.00K | Jul 13, 2020 |
Recently reported changes in QDEL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by QDEL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
QDEL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
QDEL Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| Labs | $382.90M | 60.69% |
| Immunohematology | $134.20M | 21.27% |
| Point of Care | $108.20M | 17.15% |
| Donor Screening | $4.00M | 0.63% |
| Molecular Diagnostics | $1.60M | 0.25% |
As of: Q2 2026 (Jun 28, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New QDEL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to QDEL from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in QDEL
| ETF | Est. Holding Size |
|---|---|
| IJRiShares Core S&P Small-Cap ETF | $50.46M |
| AVUVAvantis U.S. Small Cap Value ETF | $43.42M |
| VTIVanguard Morningstar Total Stock Market ETF | $31.35M |
| VBVanguard Morningstar Small-Cap ETF | $22.62M |
| IWMiShares Russell 2000 ETF | $22.54M |
| VBRVanguard Morningstar Small-Cap Value ETF | $14.38M |
Estimated from each fund’s disclosed top holdings × AUM
QDEL Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from QDEL’s recent data — informational, not investment advice
